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EtaA is a newly identified FAD-containing monooxy-
genase that is responsible for activation of several thio-
amide prodrugs in Mycobacterium tuberculosis. It was
found that purified EtaA displays a remarkably low ac-
tivity with the antitubercular prodrug ethionamide.
Hinted by the presence of a Baeyer-Villiger monooxyge-
nase sequence motif in the EtaA sequence, we have been
able to identify a large number of novel EtaA substrates.
It was discovered that the enzyme converts a wide range
of ketones to the corresponding esters or lactones via a
Baeyer-Villiger reaction, indicating that EtaA repre-
sents a Baeyer-Villiger monooxygenase. With the excep-
tion of aromatic ketones (phenylacetone and benzylac-
etone), long-chain ketones (e.g. 2-hexanone and
2-dodecanone) also are converted. EtaA is also able to
catalyze enantioselective sulfoxidation of methyl-p-
tolylsulfide. Conversion of all of the identified sub-
strates is relatively slow with typical kcat values of
around 0.02 s1. The best substrate identified so far is
phenylacetone (Km  61 M, kcat  0.017 s
1). Redox
monitoring of the flavin cofactor during turnover of
phenylacetone indicates that a step in the reductive
half-reaction is limiting the rate of catalysis. Intrigu-
ingly, EtaA activity could be increased by one order of
magnitude by adding bovine serum albumin. This reac-
tivity and substrate acceptance-profiling study provides
valuable information concerning this newly identified
prodrug activator from M. tuberculosis.
Tuberculosis is the world’s leading cause of death from a
single infectious organism. Standard tuberculosis chemother-
apy consists of a lengthy treatment with at least two so-called
first-line drugs, e.g. isoniazid and rifampicin. Unfortunately,
an increasing number of tuberculosis cases are encountered
that cannot be treated because of resistance to one or more of
these drugs (1, 2). The last resort for combating such (multi)-
drug-resistant mycobacterial infections relies mainly on the
action of second-line antitubercular drugs. For this reason,
several thioamide drugs have been successfully employed dur-
ing the last decades (Fig. 1). However, as for other antituber-
cular agents, more and more infections are encountered that
are also resistant to thioamide-based treatment. Despite their
widespread use, the mode of action of thioamide antibiotics as
well as the mechanism by which mycobacteria acquire resist-
ance against these drugs has remained obscure.
A few years ago a gene from Mycobacterium tuberculosis was
identified that is responsible for the antitubercular effect of
ethionamide, which was named etaA (3, 4). Ethionamide was
found to be activated by the corresponding protein EtaA, after
which the activated product exerts a lethal effect by interacting
with a final target. The activating role of EtaA was confirmed
by overexpression of the prodrug activator in Mycobacterium
smegmatis, resulting in ethionamide-hypersensitive mycobac-
teria. Clinically observed resistance toward the prodrug could
be associated with etaA gene mutations resulting in functional
impairment of EtaA. A thorough analysis of ethionamide-resis-
tant M. tuberculosis isolates has revealed cross-resistance to
two other widely used thiocarbamide-containing drugs, thiac-
etazone and thiocarlide (see Fig. 1) (3). In addition, it is very
likely that the antitubercular effect of prothionamide can also
be linked to activation by EtaA because it differs from ethio-
namide by only one methyl group. This indicates that EtaA
displays an exceptional broad prodrug acceptance. Further-
more, because ethionamide is also used to treat leprosy, a
similar activating enzyme is expected to be present in this
related pathogenic Mycobacterium leprae. This is in line with
the observation that, similar to M. tuberculosis, cross-resis-
tance among above-mentioned thioamides has been observed
for M. leprae (5). Genome analysis indeed shows that, despite a
dramatically reduced genome size, an etaA gene ortholog has
been conserved in the M. leprae genome (6, 7).
Recently, the primary final target of EtaA-activated ethio-
namide has been identified to be InhA, an enoyl-acyl carrier
protein reductase involved in fatty acid synthesis (8). InhA is
also the final target for another well known antitubercular
prodrug, isoniazid. Although sharing the same final target, the
prodrugs ethionamide and isoniazid are specifically activated
by two unrelated redox enzymes. While isoniazid is activated
by a heme-containing catalase-peroxidase (KatG) (9), it has
recently been shown that EtaA is a flavin-containing monooxy-
genase (10). EtaA-mediated conversion of ethionamide results
in the formation of the corresponding sulfoxide product. This
sulfoxide product does not represent the cytotoxic species but
rather has to be activated in a subsequent reaction. This second
activation step was also found to be catalyzed by EtaA yielding
2-ethyl-4-amidopyridine as final product (10). However, this
amide has no antitubercular activity, indicating that the key
toxic species is formed as an unstable reactive product inter-
mediate (3). It has been suggested that the initial sulfinate
product formed after two consecutive EtaA-mediated sulfoxi-
dations of ethionamide decomposes to form a labile toxic inter-
mediate. This intermediate would resemble activated isoniazid
inhibiting the final target InhA by forming a covalently modi-
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fied NADH derivative in the active site of InhA (11). Neverthe-
less, it has been observed that the effect of activated ethio-
namide on InhA activity differs from isoniazid-based inhibition
as inhibition cannot be prevented by the addition of NADH or
NAD (12). This finding suggests a different mode of action of
the activated product. Furthermore, it has been found that the
final target for other antitubercular thioamides may differ for
each thioamide prodrug. Different from ethionamide and iso-
niazid, thiocarlide and related thioamide compounds specifi-
cally affect the synthesis of short-chain fatty acids (13).
A sequence homology search using the EtaA sequence re-
vealed significant homology with several flavin-containing mo-
nooxygenases. Furthermore, the presence of a newly identified
sequence fingerprint (FXGXXXHXXXW(P/D)) suggests that
EtaA is a flavin-containing Baeyer-Villiger monooxygenase
(BVMO)1 (14). In fact, a search in the protein sequence data
base revealed that the closest homolog (24% sequence identity)
with known activity is 4-hydroxyacetophenone monooxygen-
ase. This BVMO has recently been cloned and expressed in our
laboratory (15) and prompted us to study the substrate speci-
ficity and reactivity of the recently identified prodrug activator
EtaA.
EXPERIMENTAL PROCEDURES
Chemicals—Restriction enzymes, NADH, NADPH, glucose oxidase
(grade II), and catalase, were obtained from Roche Applied Science.
Ketones were purchased from Acros, Aldrich, and Lancaster. NADP,
3-acetyl-NADP, and 3-amino-NADP were from Fluka. All of the other
chemicals were of commercially available analytical grade. DNA sam-
ples were purified using the QIAQuick gel and purification kit from
Qiagen. Escherichia coli TOP10-competent cells and the pBAD/myc-
HisA vector were obtained from Invitrogen. Purified recombinant
4-hydroxyacetophenone monooxygenase was obtained as described
previously (15).
Expression and Purification of Recombinant EtaA—The etaA gene
was amplified using pMH29-containing etaA as template (kindly pro-
vided by C. E. Barry, III and A. E. DeBarber, National Institutes of
Health) and the following two primers: PETA1 (5-GGCACGGCATAT-
GACCGAGCACCTCGACGTTGTC-3, NdeI site is shown underlined)
and PETA2 (5-GGCACGGAAGCTTAACCCCCACCGGGGCAGGCCT-
TTTGG-3, HindIII site is shown underlined). For expression, a pBAD-
/myc-HisA (Invitrogen) derived expression vector, pBADNK, was used
in which the original NdeI sites have been removed, whereas the NcoI
site has been replaced by a NdeI site (16). After amplification, the gene
was isolated from gel, digested with NdeI and HindIII, and ligated
behind the araBAD promoter of the NdeI/HindIII-digested pBADNK-
yielding pBETA1. Expression using pBETA1 results in the production
of EtaA containing 25 additional C-terminal residues (c-myc epitope
and His6). Expression of native EtaA was achieved by introducing a stop
codon in pBETA1 using the primers PETA3 (5-GCCCCGGTGGGGG-
TTTGAAAGCTTGGGCCCGAAC-3, HindIII site is shown underlined)
and PETA4 (5-GTTCGGGCCCAAGCTTTCAAACCCCCACCGGGGC-
3, HindIII site is shown underlined) resulting in pBETA2. For expres-
sion, E. coli TOP10 cells were transformed with pBETA1 or pBETA2
and grown in LB medium supplemented with 100 g/ml ampicillin and
0.02% (w/v) arabinose at a temperature of 25 °C.
His-tagged EtaA was purified using the following procedure. Cells
from a 2-liter culture were harvested by centrifugation and resus-
pended in TMAG (50 mM Tris, 100 mM KCl, 1 mM -mercaptoethanol, 1
mM NaN3, 10% v/v glycerol, pH 7.5, containing 1% (v/v) Triton X-100).
After sonication and centrifugation, the resulting supernatant was
added to nickel-agarose affinity column material with a capacity of 50
mg. By means of end-over-end rotation, the column material was re-
suspended with the extract and incubated for 1 h at 4 °C. After incu-
bation, the column material was washed by gravitational flow. Upon
washing the column with 10 column volumes of TMAG and 10 column
volumes of TMAG containing 20 mM imidazole, the enzyme was washed
from the column with TMAG containing 400 mM imidazole. To remove
the imidazole, the collected enzyme fraction was applied to a preequili-
brated Hi-prep 26/10-desalting column (Amersham Biosciences). Fi-
nally, the enzyme was concentrated by using an Amicon ultrafiltration
unit equipped with a 100-kDa cut-off filter and stored at 80 °C.
Native EtaA was purified using three columns. The harvested cells
were resuspended in buffer (20 mM potassium phosphate, 1 mM -mer-
captoethanol, 1 mM NaN3, 10% v/v glycerol, pH 7.5), sonicated, and
centrifuged. In the first column step, the extract was applied onto a
Q-Sepharose column. The enzyme could be eluted using 250 mM KCl. In
the second step, the collected enzyme fraction was applied onto a
ceramic hydroxyapatite column (2.5  12 cm, Type I, particle size 20
m, Bio-Rad) equilibrated with 20 mM potassium phosphate, pH 7.0.
The enzyme was eluted using a gradient of 20–300 mM potassium
phosphate. Active fractions were concentrated by ultrafiltration and
applied to a 26/60 Superdex 200 column (Amersham Biosciences).
Again, active fractions were pooled and concentrated by ultrafiltration
and subsequently stored at 80 °C.
Analytical Methods—Analytical size-exclusion chromatography was
performed using a Superdex 200 HR 10/30 column (Amersham Bio-
sciences) using TMAG with or without 0.5 mg/ml BSA. Aliquots of 100
l were loaded on the column and eluted at a flow rate of 0.8 ml/min.
Apparent molecular masses were determined using a calibration curve
made with standards from the molecular mass marker kit from Bio-
Rad: thyroglobulin (670 kDa); bovine  globulin (158 kDa); chicken
ovalbumin (44 kDa); equine myoglobin (17 kDa); and vitamin B12 (1.35
kDa).
Enzyme activity with all of the tested ketones was determined spec-
trophotometrically by monitoring the decrease of NADPH at 340 nm
(
340 nm
 6.22 mM1 cm1). Conversion of ethionamide was measured by
monitoring the formation of the ethionamide-oxide product at 400 nm
(
400 nm
 1.0 mM1 cm1). Reaction mixtures (1.0 ml) typically contained
50 mM Tris/HCl, pH 8.5, 0.2 mM NADPH, and 1.0 M enzyme. For
determining the Km for NADPH, 1.0 mM phenylacetone was used as
substrate. For measuring the effect of additives, 0.5 mM phenylacetone
and 0.2 mM NADPH were used. All of the kinetic measurements were
performed at 25 °C using air-saturated buffers.
The redox potential of EtaA was determined by the method of Massey
(17). Enzyme (5 M) in the presence of 2 M methyl viologen, 5 M
phenosafranin (Em  252 mV), 200 M xanthine, and 10% (w/v)
1 The abbreviations used are: BVMO, Baeyer-Villiger monooxygen-
ase; EtaA, ethionamide monooxygenase; BSA, bovine serum albumin;
GC-MS, gas chromatography-mass spectrometry; FAD, flavin adenine
dinucleotide.
FIG. 1. Structural formulas of some
thiocarbamide-containing antituber-
culosis drugs.
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glycerol in 50 mM Tris/HCl, pH 7.5, was made anaerobic in a cuvette by
flushing with nitrogen. Reduction was initiated by adding 0.5 g/ml
xanthine oxidase and subsequently monitored using a PerkinElmer
Lambda Bio 40 spectrophotometer (at 25 °C). Spectra (300–700 nm)
were recorded every minute until the reduction of both dye and enzyme
was complete (1.5 h). Reduction of the dye was measured at 520 nm,
whereas flavin reduction could be followed at 404 nm.
Product Identification—For product identification, samples (1.0 ml)
containing 5 mM of substrate, 2.5 mM NADPH, and 2 M EtaA were
incubated for 24 h at 25 °C. The reaction was quenched by adding 1.0 ml
of ethyl acetate containing 1.0 mM hexadecane. The ethyl acetate layer
was collected and dried over MgSO4 and subsequently analyzed by
GC-MS. GC-MS analysis was performed on a Hewlett Packard HP 5890
series II gas chromatograph and a Hewlett Packard HP 5971 mass
spectrometer equipped with an HP-5 column. Samples (1 l) were
injected without derivatization and using the following temperature
program: a gradient from 50 to 150 °C in 10 min, 4-min isothermal at
150 °C followed by a gradient from 150 to 300 °C in 3 min, and finally
12-min isothermal at 300 °C. The enantioselective sulfoxidation of
methyl-p-tolylsulfide was monitored by GC using a Chiraldesc G-TA
column (30 m  0.25 mm) (16).
RESULTS
Purification and Spectral Characterization of Recombinant
EtaA—EtaA containing a His6 and c-myc epitope tag at the C
terminus was purified from cell extracts in the presence of
Triton X-100. From 1 liter of culture, 15 mg of recombinant
protein could be purified. The purified enzyme migrated as a
single band in SDS-PAGE corresponding to a mass of56 kDa.
This value is close to the theoretical mass of the recombinant
protein (58,216 Da). Elimination of the detergent from the
purification buffer resulted in very low yields (10% compared
with the addition of 0.1% Triton X-100), suggesting that the
enzyme is membrane-associated. Solubilization of EtaA by Tri-
ton X-100 has been observed previously (10). However, no clear
hydrophobic segments could be identified in the EtaA sequence
that could serve as a membrane anchor. The EtaA sequence
shows homology with a number of other flavin-containing mo-
nooxygenases that are all known to be monomeric or dimeric
soluble proteins (14). Nonetheless, it was found that EtaA
tends to form oligomers as evidenced by gel filtration experi-
ments. Gel filtration experiments performed in this study
showed that the enzyme exists as a mixture of relatively large
oligomers ranging from 200 to 600 kDa.
Compared with His-tagged EtaA, purified native EtaA dis-
played similar hydrodynamic properties and showed the same
activity toward ethionamide (see below). As purification of His-
tagged enzyme is very efficient, this EtaA variant has been
used for all of the experiments described below.
EtaA was purified as a brightly yellow protein indicating
that it contains a tightly bound flavin cofactor, which has
previously been identified as FAD (10). Spectral analysis of the
purified recombinant enzyme showed a typical flavin spectrum
displaying absorbance maxima at around 367 and 451 nm (Fig.
2). The ratio in absorbance at 280 and 451 nm for the purified
protein was typically 16. This ratio was found to be the same
for all of the oligomeric species observed upon gel filtration,
indicating that flavin content is not dependent on the oligo-
meric state. Unfolding of the enzyme by 0.05% SDS resulted in
a rapid release of the flavin cofactor allowing quantification of
the released cofactor. Combining the determined cofactor and
protein subunit concentrations showed that the purified en-
zyme contains stoichiometric (1:1) amounts of the flavin cofac-
tor. The molar extinction coefficient for EtaA could be calcu-
lated using the known value of free FAD (451 nm EtaA  11,600
M1 cm1).
Catalytic Properties of EtaA—To probe whether all of the
EtaA-bound FAD participates in catalysis, the enzyme was
mixed anaerobically with an excess of NADPH (Fig. 2). It was
found that the enzyme was slowly reduced by the nicotinamide
coenzyme. Comparing the spectrum reached after 30-min incu-
bation with NADPH with the spectrum obtained by reduction
with dithionite shows that the enzyme is almost fully reduced.
The fact that the enzyme is able to bind and react with NADPH
indicates that the enzyme is folded and catalytically competent.
No significant flavin reduction could be measured when using
NADH. This is in line with the observation that all of the char-
acterized sequence-related monooxygenases are highly specific
for NADPH (14). Aerobic incubations with NADPH revealed that
the enzyme catalyzes a slow oxidation of NADPH (0.0045 s1)
generating hydrogen peroxide. A low NADPH oxidase activity
has also been observed with other BVMOs (15, 19).
Using ethionamide and NADPH as substrates, a relatively
slow sulfoxidation of the thioamide could be observed, confirm-
ing the activating role of EtaA. Conversion of ethionamide
could be directly monitored by measuring the absorbance of the
sulfoxide product at 400 nm (10). Oxygen concentration was not
limiting the rate of ethionamide conversion because using ox-
ygen-saturated solutions did not increase the conversion rate.
The determined steady-state kinetic parameters of EtaA for
ethionamide oxidation suggest that ethionamide is a remark-
ably poor substrate for the prodrug activator displaying a rel-
atively low kcat value of 0.027 s
1 and a Km of 340 M (Table I).
Such a low rate of conversion does not seem to be of physiolog-
ical importance because conversion rates (kcat) for FAD-con-
taining monooxygenases typically range from 1 to 30 s1 (18,
20). In fact, it is difficult to envisage that such an inefficient
prodrug activation can initiate the bactericidal effect observed
in mycobacteria. The enzyme was found to be efficient in
NADPH recognition displaying a Km of 10 M using ethio-
namide as oxygenating substrate. This value is similar to those
found for other sequence related-monooxygenases (18).
It is known that flavin-containing monooxygenases can with
the exception of catalyzing oxygenations also generate hydro-
gen peroxide. In fact, the addition of certain effector molecules
can accelerate such a NADPH oxidase activity. For example,
the FAD-containing 2-hydroxybiphenyl 3-monooxygenase from
Pseudomonas azelaica HBP1 uses, depending on the substrate,
only a small part of all consumed NADPH molecules to hydrox-
ylate the substrate, whereas all of the other electron equiva-
lents are used for hydrogen peroxide formation (21). Because
hydrogen peroxide is a potent oxidative agent, it was impera-
tive to test whether the observed sulfoxidation reactions cata-
lyzed by EtaA are truly enzyme-mediated. For this reason, we
FIG. 2. Spectral changes observed upon reduction of EtaA.
EtaA (6.3 M) was anaerobically reduced by 150 M NADPH in 50 mM
Tris/HCl, pH 8.5. Spectra (from top to bottom) were recorded at t  0, 5,
10, 15, 20, and 30 min. A spectrum of fully reduced EtaA (—) was
obtained by adding dithionite. Aerobic incubation of EtaA with 440 M
NADPH and 430 M phenylacetone shows that the enzyme is mainly in
the oxidized form during steady-state turnover (, spectra obtained
after 2-min incubation).
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examined the EtaA-mediated conversion of methyl-p-tolylsul-
fide, a sulfide that is readily accepted by other flavin-depend-
ent monooxygenases as substrate (18). It was found that EtaA
catalyzes an enantioselective oxygenation of this sulfide, yield-
ing mainly the S-sulfoxide (55% enantiomeric excess). The ad-
dition of catalase to the incubation mixture did not influence
the observed enantioselectivity. These results indicate that the
sulfide is oxidized in the active site of EtaA by reacting with the
electrophilic hydroperoxy form of the flavin cofactor (18), con-
firming a direct role of EtaA in sulfide oxidation.
EtaA Catalyzes Baeyer-Villiger Reactions—Hinted by the
presence of a BVMO identifying sequence motif in the EtaA
sequence (14), we tested a range of ketones that have been
shown to be converted by BVMOs. It was found that several
typical BVMO substrates (cyclohexanone, acetophenone, and
4-hydroxyacetophenone) were not accepted by EtaA. Incuba-
tions with these ketones did not increase consumption of
NADPH nor could the expected lactone or ester products be
detected by GC-MS analysis. However, although the addition of
bicyclohept-2-en-6-one did not increase the rate of NADPH
oxidation, a small amount (1% conversion) of a Baeyer-Vil-
liger oxidation product, 3-oxabicyclo[3.3.0]oct-6-en-2-one, could
be detected. This prompted us to test more aliphatic ketones.
By GC-MS analysis, it was found that a surprisingly broad
range of ketones was converted by EtaA (Table I). Besides
several long-chain alkanones ranging from 2-hexanone to 2-do-
decanone, phenyl substituent-bearing ketones also are con-
verted via a Baeyer-Villiger reaction into the corresponding
esters. With the exception of the long-chain alkanones 2-oc-
tanone, 2-decanone, and 2-dodecanone, conversion of all of the
ketones resulted in the formation of the expected ester product.
In the case of 3-octanone, 2-decanone, and 2-dodecanone, some
formation of the chemically less favored ester products could
also be detected. By this, EtaA-mediated oxidation obeys the
stereochemical rule of Baeyer-Villiger oxidation reactions
where the oxygen is typically inserted by migration of the most
substituted alkyl chain. For some of the identified substrates,
the steady-state parameters were determined (Table II). Re-
markably, all of the measured kcat values are in the same range
as determined for ethionamide. Only the Km values varied to a
significant extent, revealing that phenylacetone is the best
substrate found so far.
The similar kcat values found for all of the tested substrates
suggest that the rate of oxygenation is determined by a shared
slow event along the catalytic cycle. By determining the redox
state of the enzyme during turnover, it can be established
which half-reaction comprises this rate-limiting event. For
these flavin-monitored turnover experiments, the absorbance
at 440 nm was taken as the indicator for the presence of
oxidized enzyme. By incubating the enzyme with saturating
amounts of substrate, the redox state of EtaA during conver-
sion of ethionamide, benzylacetone, phenylacetone, and 2-do-
decanone was determined. For all of the tested substrates, it
was found that the enzyme is mainly present in the oxidized
state, indicating that a catalytic step in the reductive half-
reaction is limiting the rate of catalysis.
During the reductive half-reaction, a hydride is transferred
from the NADPH coenzyme to the flavin cofactor. This redox
reaction will only proceed when the redox potential of the
electron acceptor, the flavin cofactor, is higher relative to the
redox potential of NADPH (320 mV). Using the method de-
scribed by Massey (17), the redox potential of EtaA was deter-
mined. During reduction of EtaA, no flavin radical intermedi-
ate could be observed, indicating that the reaction involves a
2-electron reduction. For determining the redox potential, phe-
nosafranin (Em252 mV) could be used as reference because
reduction of this dye almost coincides with reduction of EtaA.
Using the difference between the log(red
ox ) values of the dye and
EtaA during reduction, the redox potential for EtaA could be
estimated: 245  3 mV. This value is somewhat lower then
the value for free FAD (-207 mV) and similar to values reported
for other flavin-dependent monooxygenases (17, 22, 23). The
measured redox potential is also in the expected range to facil-
itate reduction of the FAD cofactor by NADPH.
Identification of EtaA Activators and Inhibitors—Because
the activity of EtaA with all of the uncovered substrates is very
low, several compounds were tested for their activating or
inhibiting effect (Table III). Because the enzyme appears to be
membrane-associated (10), the influence of several detergents
on activity was investigated. The addition of all of the tested
detergents only resulted in decreased activities. For sequence
related eukaryotic flavin-containing monooxygenases, specific
activators have been found (24, 25). However, the tested com-
pounds, n-octylamine and reduced glutathione, did not signif-
icantly affect EtaA activity. A striking effect was found when
using bovine serum albumin as additive. The addition of this
TABLE I
Identified EtaA substrates and corresponding products
In case of formation of two products the ratio in product formation as
estimated by GC analysis is indicated.
a Product has been identified by Vannelli et al. (10).
TABLE II
Steady-state kinetic parameters of EtaA
Substrate KM kcat FMT
a
M s1 %
Ethionamide 340 0.027 88
Phenylacetone 61 0.017 90
Benzylacetone 520 0.021 91
2-Dodecanone 200 0.023 94
a The flavin-monitored turnover (FMT) value indicates the percent-
age of oxidized cofactor during turnover.
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protein increased the activity by one order of magnitude (Table
III). By varying BSA concentrations, it was found that already
at an equimolar concentration of BSA, EtaA activity was sig-
nificantly increased (Fig. 3). Kinetic analysis using phenylac-
etone as substrate revealed a 15-fold increase in kcat while the
Km value also significantly increased when 6 M BSA was
added (kcat  0.26 s
1, Km  280 M). Monitoring the flavin
cofactor during conversion of phenylacetone revealed that the
addition of bovine serum albumin increases the rate of flavin
reduction. While in the absence of bovine serum albumin, the
flavin is mainly in the oxidized state (Table II) and the reduc-
tive and oxidative half-reactions are almost balanced when
bovine serum albumin is added (56% of the flavin is oxidized
during catalysis). An increased rate of reduction is in line with
the observed increase in kcat and Km values when a similar
catalytic mechanism is operative as found for related flavin-
containing monooxygenases (24).
To probe the effect of BSA on the oligomerization behavior of
EtaA, a gel filtration experiment was performed using 6 M
BSA in the elution buffer. It was found that BSA did not affect
the elution pattern because again a distribution of oligomers
ranging for tetramers to decamers was observed. Apparently,
the activating effect of BSA does not involve dissociation of
oligomeric EtaA. These results suggest that EtaA is activated
in vivo by protein-protein or interactions with other cellular
components. Although bovine serum albumin is frequently
used to stabilize enzymes in solution, an activating effect by
this protein has been rarely reported. Interestingly, an activat-
ing effect by bovine serum albumin has also been observed with
another BVMO, which acts on similar aliphatic substrates (26).
Besides exploring the effect of potential activators, a known
flavoprotein inhibitor, diphenyleneiodonium, was also tested.
However, no inhibitory effect was detected, which might indi-
cate that the active site is not accessible for this relatively
bulky compound (27). For the well studied BVMO, cyclohex-
anone monooxygenase, it is known that NADP is an effective
competitive inhibitor (22). The affinity of EtaA for NADP and
other coenzyme analogs was also probed (Table III). Both
NADP and NAD were found to be poor inhibitors. NADP
analogs differing in the nicotinamide moiety (3-acetyl-NADP
and 3-amino-NADP) showed significant inhibition. 3-Amino-
NADP had a dramatic effect on activity as only 26% of the
normal activity was measured with a relatively low inhibitor
concentration (50 M). This indicates that 3-amino-NADP can
bind tightly to the NADPH binding pocket while the reaction
product NADP cannot. Because the binding of 3-amino-
NADP might mimic the binding of NADPH close to the flavin
cofactor, the redox potential of EtaA in the presence of 50 M
3-amino-NADP was measured. It was found that binding of
this inhibitor results in a small upward shift of 11 mV: Em 
234  3 mV.
Activation of Ethionamide by 4-Hydroxyacetophenone Mo-
nooxygenase—As mentioned above, EtaA shares significant se-
quence identity with a bacterial BVMO, 4-hydroxyacetophe-
none monooxygenase. To check whether the sequence homology
also extends to shared catalytic properties, the activity of 4-hy-
droxyacetophenone monooxygenase with ethionamide was
tested. It was found that the enzyme rapidly converts ethio-
namide into the corresponding sulfoxide (kcat  1.1 s
1, Km 
330 M). Similar to EtaA (10), 4-hydroxyacetophenone mo-
nooxygenase was also found to perform the subsequent oxida-
tion of the formed sulfoxide since prolonged incubations re-
sulted in the loss of absorbance at 400 nm. By comparing the
steady-state kinetic parameters for ethionamide and NADPH
for both bacterial monooxygenases, it can be concluded that
4-hydroxyacetophenone monooxygenase is very efficient in ox-
idizing ethionamide. In fact, the corresponding kcat value is in
the same range as found for 4-hydroxyacetophenone, its phys-
iological substrate (15). Similar to EtaA, 4-hydroxyacetophe-
none monooxygenase is also able to sulfoxidize methyl-p-tolyl-
sulfide forming the S-sulfoxide in high enantiomeric excess
(	99%) (16). No activity with phenylacetone could be detected,
indicating that the substrate profiles of both monooxygenases
are not fully overlapping. Nevertheless, the relatively high
activity of 4-hydroxyacetophenone monooxygenase with ethio-
namide indicates that this monooxygenase represents a con-
venient model enzyme to study the mechanism of ethionamide
activation.
DISCUSSION
For decades, thioamides have been used to treat mycobacte-
rial infections. Recently, it has been established that in
M. tuberculosis, the toxicity of the most commonly used thio-
amide, ethionamide, depends on activation by a specific pro-
drug activator (3, 4). This activator, EtaA, represents a
NADPH-specific FAD-containing monooxygenase (10). Se-
quence analysis suggested that the monooxygenase is member
of a newly identified family of BVMOs (14). In this study, we
have been able to demonstrate that EtaA is indeed able to
perform Baeyer-Villiger oxidations reactions. The ability to
catalyze such atypical oxygenation reactions and the relatively
TABLE III




Triton X-100 0.1 % 65
Tween 20 0.1 % 20
Laurylsarcosine 0.1 % 0
Reduced glutathione 10 mM 60
n-Octylamine 5 mM 110
Bovine serum albumin 2 mg/ml 930
Diphenyleneiodonium 0.5 mM 100
Coenzyme analogs
NADP 0.5 mM 86
NAD 0.5 mM 86
AMP 0.5 mM 80
3-Acetyl-NADP 0.5 mM 50
3-Amino-NADP 0.05 mM 26
FIG. 3. Activation of EtaA by BSA. The activity of EtaA (2.2 M)
was measured in the presence of varying concentrations of BSA (0–3.1
M) using 150 M NADPH and 500 M phenylacetone in 50 mM Tris/
HCl, pH 8.5.
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high degree of sequence identity with other BVMOs suggests
that in vivo EtaA is functioning as a BVMO. The kinetic anal-
yses have shown that the observed low turnover rates of the
isolated enzyme are because of a relatively low reduction of
EtaA by NADPH. It was found that this poor coenzyme reac-
tivity can be significantly increased by adding bovine serum
albumin. This indicates that the activity of EtaA in M. tuber-
culosis is modulated by interaction with other cellular
components.
Although being a BVMO EtaA accepts ketones as substrate,
the exact nature of the physiological substrate(s) remains to be
established. Most BVMOs identified so far are involved in the
degradation of ketones ranging from small growth substrates
like acetol (28) to relatively bulky ketones like cyclododecanone
(29). Recent studies have revealed that these bacterial BVMO
genes typically are part of an operon, which typically includes
a esterase gene to hydrolyze the ester formed by the respective
BVMO. However, etaA is not part of an operon as it has been
found to be directly and singly regulated by a neighboring
regulator gene ethR (4).
All of the mycobacterial genomes sequenced so far contain
an etaA gene ortholog showing sequence identity of 100%
(M. tuberculosis CDC1551 and Mycobacterium bovis), 85%
(Mycobacterium marinum), 81% (Mycobacterium ulcerans),
80% (M. leprae), 67% (Mycobacterium paratuberculosis), 67%
(Mycobacterium avium), and 65% (M. smegmatis). Also, the
associated regulator gene ethR is conserved in mycobacteria
(4). Interestingly, from the six BVMO genes identified in
M. tuberculosis, only the etaA ortholog (80% sequence identity)
can be identified in M. leprae. Apparently, EtaA is the only
BVMO that has survived in M. leprae, reflecting the drastic
reduction in genome size of this human pathogen (6). Preser-
vation of the etaA gene in all of the sequenced mycobacterial
genomes suggests that this BVMO serves an important physi-
ological role in mycobacteria. However, EtaA does not seem to
be of vital importance for the bacterium because it has been
shown that ethionamide-resistant M. tuberculosis isolates har-
bor etaA gene mutations, preventing the production of func-
tional EtaA (3). Nevertheless, malfunctioning of EtaA might be
rescued to some extent by one or more of the other BVMOs
because BVMOs typically display promiscuity in substrate
specificity (18).
Because most microbial genomes are lacking BVMO genes,
the identification of six BVMOs in the genome of M. tubercu-
losis is striking. Genome analysis of partially and fully se-
quenced mycobacterial genomes using the BVMO sequence
motif reveals that mycobacteria typically contain a relatively
large number of BVMOs. Most mycobacterial genomes contain
roughly five BVMO genes. At this moment, the record has been
set by M. marinum containing at least 15 BVMO genes. In line
with this scenario, it has been noted before that M. tuberculosis
contains a relatively large amount of oxidative enzymes includ-
ing 20 cytochromes P450s (30). The reason for this abundance
of oxidative potential in mycobacteria is as yet unknown. It has
been suggested that activity of a large number of oxidizing
enzymes in M. tuberculosis might help the pathogenic orga-
nism to survive oxidative stress conditions as encountered in
the human macrophage (3). In this context, it can be envisaged
that EtaA and/or other mycobacterial BVMOs can play a role in
the removal of toxic ketones. The observed exceptional broad
substrate specificity of EtaA is in line with fulfilling such a
detoxifying function. However, all of the BVMOs characterized
so far have been shown to be involved in a specific metabolic
process. Because the etaA gene is conserved in other mycobac-
teria, EtaA might also serve a role in a metabolic pathway that
is specific for mycobacteria. Typical components of the myco-
bacterial cell wall are mycolic acids. It has been shown that the
ability of mycobacteria to synthesize the so-called wax ester
mycolic acids relies on a Baeyer-Villiger oxidation step (31, 32).
The BVMO responsible for the synthesis of these wax ester
mycolic esters has never been identified. Recently, it has also
been suggested that a key step in the degradation of mycolic
acids is catalyzed by a BVMO (33). The ability of EtaA to
convert relatively hydrophobic substrates and its membrane
association would fit well with a function in mycolic acid me-
tabolism. Future biochemical studies should clarify the role of
EtaA and its homologs in mycobacterial physiology.
BVMOs are frequently encountered in genomes of mycobac-
terial pathogens (14, 34, 35). It has even been found that a
major part of a BVMO gene (accession number L04542)2 can be
used for PCR-based detection of pathogenic M. avium isolates
(36). With the exception of a prevalence of BVMOs in mycobac-
teria, BVMO genes have also been found in other pathogenic
microorganisms (37, 38). BVMOs typically display a broad sub-
strate specificity while exhibiting high regio- and enantioselec-
tivity (18). Furthermore, no BVMOs have been identified in
plants, animals, or human. This indicates that members of this
class of monooxygenases are ideally suited to exploit as prodrug
activators because no competing activities exist in the host of
these intracellular pathogens, although they catalyze a wide
range of selective oxidative reactions. Effective treatment of
mycobacterial infections using thioamides (e.g. ethionamide)
has already shown that the BVMO EtaA can indeed serve as an
effective prodrug activator. The identification a new substrate
class and corresponding reactivity (Baeyer-Villiger oxidation)
for this thioamide activator opens new opportunities for devel-
oping chemotherapy for treating mycobacterial infections
based on the activity of EtaA or one of its homologs.
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